Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients

Objective. Vasculopathy is a key factor in the pathophysiology of systemic sclerosis (SSc) and the main cause for Raynaud phenomenon (RP), digital ulcers (DU), and/or pulmonary arterial hypertension (PAH). It is so far unknown how patients with SSc are treated with vasoactive agents in daily practice. To determine to which extent patients with SSc were treated with different vasoactive agents, we used data from the German Network for Systemic Scleroderma registry. Methods. The data of 3248 patients with SSc were analyzed. Results. Patients were treated with vasoactive drugs in 61.1% of cases (1984/3248). Of these, 47.6% received calcium channel inhibitors, followed by 34.2% treated with angiotensin-converting enzyme (ACE) inhibitors, 21.1% treated with intravenous (IV) prostanoids, 10.1% with pentoxifylline, 8.8% with angiotensin 1 receptor antagonists (AT1RA), 8.7% with endothelin 1 receptor antagonists (ET1RA), 4.1% with phosphodiesterase type 5 (PDE5) inhibitors, and 5.3% with others. Patients with RP received vasoactive therapy in 63.3% of cases, with DU in 70.1%, and with PAH in 78.2% of cases. Logistic regression analysis revealed that patients with PAH were significantly more often treated with PDE5 inhibitors and ET1RA, and those with DU with ET1RA and IV prostanoids. In addition, 41.8% of patients were treated with ACE inhibitors and/or AT1RA. Patients registered after 2009 received significantly more often ET1RA, AT1RA, and IV prostanoids compared with patients registered prior to 2005. Conclusion. These data clearly indicate that many patients with SSc do not yet receive sufficient vasoactive therapy. Further, in recent years, a marked change of treatment regimens can be observed.

[1]  Sohita Dhillon.  Macitentan: A Review of Its Use in Patients with Pulmonary Arterial Hypertension , 2014, Drugs.

[2]  E. Rosato,et al.  In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension. , 2014, Rheumatology.

[3]  M. Worm,et al.  Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis , 2014, Annals of the rheumatic diseases.

[4]  J. Pope,et al.  Meta‐Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis , 2013, Arthritis care & research.

[5]  S. Kaur,et al.  Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis–related pulmonary artery hypertension and cutaneous vascular complications , 2013, Rheumatology International.

[6]  M. Roustit,et al.  Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials , 2013, Annals of the rheumatic diseases.

[7]  J. Pope,et al.  Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. , 2012, Seminars in arthritis and rheumatism.

[8]  M. Baron,et al.  Agreement with Guidelines from a Large Database for Management of Systemic Sclerosis: Results from the Canadian Scleroderma Research Group , 2012, The Journal of Rheumatology.

[9]  J. Pope,et al.  Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis , 2011, The Journal of Rheumatology.

[10]  M. Matucci-Cerinic,et al.  Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. , 2011, Autoimmunity reviews.

[11]  C. Denton,et al.  Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management , 2010, European Respiratory Review.

[12]  M. Mayes,et al.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial , 2010, Annals of the rheumatic diseases.

[13]  G. Burmester,et al.  Concise Report , 2022 .

[14]  M. Humbert,et al.  Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. , 2009, Rheumatology.

[15]  W. Lehmacher,et al.  High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy , 2009, Arthritis research & therapy.

[16]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[17]  M. Matucci-Cerinic,et al.  Digital ulcers and outcomes assessment in scleroderma. , 2008, Rheumatology.

[18]  W. Lehmacher,et al.  The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement , 2008, Rheumatology.

[19]  G. Riemekasten,et al.  Management of cutaneous vascular complications in systemic scleroderma: experience from the German network , 2008, Rheumatology International.

[20]  M. Cerinic,et al.  Vascular complications of scleroderma. , 2007, Autoimmunity reviews.

[21]  G. Riemekasten,et al.  Vasoactive therapies in systemic sclerosis. , 2006, Rheumatology.

[22]  C. Denton,et al.  Digital ulcers: overt vascular disease in systemic sclerosis. , 2006, Rheumatology.

[23]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[24]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[25]  D. Badesch,et al.  Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.

[26]  V. Welch,et al.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. , 2001, Arthritis and rheumatism.

[27]  A. Blann,et al.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. , 1999, Arthritis and rheumatism.

[28]  S. Chrysant,et al.  Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. , 1998, American heart journal.

[29]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[30]  J. Laragh,et al.  Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. , 1982, Arthritis and rheumatism.

[31]  G. Riemekasten,et al.  [Management of digital ulcers in patients with systemic sclerosis]. , 2012, Deutsche medizinische Wochenschrift.

[32]  G. Riemekasten,et al.  Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. , 2011, VASA. Zeitschrift fur Gefasskrankheiten.

[33]  E. Klings,et al.  Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. , 2006, Treatments in respiratory medicine.

[34]  R. Wise,et al.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. , 1992, The Journal of rheumatology.